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Objective To study the emergence of macrolide resistance in throat ﬂora following
treatment with clarithromycin or azithromycin.
Methods Throat samples were collected before and after treatment and plated as a lawn
on Columbia blood agar with an erythromycin E test strip. Minimum inhibitory con-
centrations (MICs) of erythromycin, clarithromycin and azithromycin were determined
against isolates of distinct morphology with erythromycin E test MIC results equal to or
greater than 2mg/L. Polymerase chain reaction techniques were used to determine the
genetic mechanisms of resistance.
Results There were 749 resistant isolates of which 474 (63%) were streptococci. Only a
quarter of the patients had no resistant streptococci before treatment started. There were
increases in the numbers of resistant isolates and in the number of patients carrying a
resistant ﬂora during and after treatment. Themost common genes identiﬁedweremefA/
E in isolates with low-level resistance and ermA/M in isolates with high-level resistance.
Conclusions There is a pool of streptococci carrying genes associated with macrolide
resistance in the normal respiratory ﬂora of generally healthy adults. Differences between
the patients treated with clarithromycin and those treated with azithromycin were
difﬁcult to assess because of the large number of patients in each group with macro-
lide-resistant streptococci before treatment. Although there were some differences these
were not statistically signiﬁcant.
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INTRODUCTION
It is well known that resistance rapidly emerges
among oral streptococci in patients treated with
a variety of antibiotics, including penicillin and
erythromycin. Clinical trials seldom concern them-
selves with such effects of antimicrobial che-
motherapy on the normal ﬂora. However, it has
recently been suggested that macrolide com-
pounds that have a long half-life and low serum
concentrations may be more prone to select a
resistant ﬂora [1], whether among pathogens such
as Streptococcus pyogenes and pneumococci, or
among commensals, which might then pass on
their resistance genes to such pathogens.
We examined the oral streptococci from patients
before and after administration of either azithro-
mycin, which has a long half-life and low serum
concentrations, or clarithromycin, which has a
shorter half-life and no extended low serum con-
centration tail. We also characterized the genetic
mechanisms of macrolide resistance detected in
the isolates.
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METHODS
Patients
The subjects studied were nonpregnant patients
over 18 years of age, attending any one of four
general practices in different regions of England
participating in the study, with signs and symp-
toms of respiratory tract infection, but otherwise
in good general health, and considered eligible
for treatment with a macrolide. Those who
had received any antibiotic within the previous
2weeks (4weeks if long-acting and parenteral)
and any macrolide within 6weeks were excluded.
The patients were randomly allocated (on the basis
of speciﬁc computer-generated instructions in
closed envelopes) to receive treatment with either
azithromycin 500mg once daily for 3 days, or
clarithromycin 500mg daily (250mg twice daily)
for 7 days. Treatment was open labelled to the
general practitioner. It was intended that each
practitioner would recruit at least 25 patients,
giving a total of at least 100 patients, of whom
75 were expected to be evaluable. Compliance was
assessed at a visit within 48 h of the completion of
treatment, when the response was assessed for
clinical management but not for the purposes of
the trial, and patients were asked to attend for
follow-up sample collection. Written informed
consent was obtained from all patients participat-
ing. The appropriate Local Ethics Committee for
each of the general practitioners approved the
study.
Samples
Throat samples were collected by the four general
practitioners on cotton swabs between September
1997 and March 1998, placed in Amies transport
medium (Probact transport swabs, Technical Ser-
vices Consultants Ltd., Heywood, UK), labelled
with a unique patient number so that therapy was
blinded to the laboratory, and posted to the Micro-
biology Laboratory at St. Thomas’ Hospital, Lon-
don. This system had been shown in preliminary
experiments to preserve the aerobic oral ﬂora for a
suitable period at ambient temperature. Throat
swabs were collected from the patients on the
occasion of their ﬁrst visit to the general practi-
tioner, within 48 h of the end of treatment, and
subsequently after about 3 and 5–6weeks. Upon
receipt in the laboratory, samples were inoculated
as a lawn on blood agar (BA: Columbia agar,
Oxoid, Basingstoke, UK), containing 5% v/v deﬁ-
brinated horse blood (TCSMicrobiology, Claydon,
UK). The lawns were allowed to dry and an ery-
thromycin E test strip (AB Biodisk, Solna, Sweden)
was placed in the center of the plate, which was
then incubated for 18–24 h at 37 8C in air. The
original specimen was held in 7% glycerol broth
at 70 8C and swabs that produced cultures over-
grown with Gram-negative bacilli or yeasts were
reinoculated on BA supplemented with nalidixic
acid 10mg/L (Sigma, Poole, UK) and amphoter-
icin B 1mg/L (Sigma) and incubated as before.
Resistant streptococci
Colonies of distinct morphology growing within
the ‘sensitive’ elipse around the E test strip, and
thus with minimum inhibitory concentrations
(MICs) presumed to be equal to or greater than
2mg/L, were roughly quantiﬁed and subcultured
to fresh purity plates. Isolates were identiﬁed by
Gram staining, and if they were found to be Gram-
positive cocci, they were identiﬁed further by
the Crystal Gram-positive Identiﬁcation system
(Becton Dickinson, Oxford, UK). If results in the
Crystal system were inconclusive, isolates were
further tested by Rapid ID 32 Strep (bioMe´rieux,
Basingstoke, UK).
MICs of erythromycin, clarithromycin and azi-
thromycin against these resistant streptococci
were determined by the BSAC agar dilution
method [2]: inocula of 104 colony-formong units
(CFU) were applied by a multipoint inoculator
(Denley, Basingstoke, UK) to Iso-Sensitest agar
(Oxoid, Basingstoke, UK) containing 5% lysed
horse blood and incubated for 18–24 h in air
at 37 8C. Staphylococcus aureus NCTC 6571 was
used as a control. The MIC was deﬁned as the
lowest concentration that completely inhibited
growth.
Non-correlating strains (that is, isolates with
E test primary MICs equal to or greater than
2mg/L but lower agar-dilution MICs) were
further tested by a double-disc diffusion assay
to determine the presence of macrolide (M) or
microlide, lincosamide, streptogramin B (MLSB)
resistance. Erythromycin (5 mg) and clindamycin
(2 mg) discs were placed 14mm apart on Columbia
agar supplemented with 5% horse blood, and
incubated overnight at 37 8C. Blunting of the clin-
damycin zone indicated inducible resistance,
while no zone around clindamycin with a reduced
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or absent zone around erythromycin indicated
constitutive resistance.
Genetic mechanisms of resistance
Polymerase chain reaction (PCR)
Total genomic DNA was isolated from macrolide-
resistant strains by the method of Ausbel et al. [3].
For maximum lysis, streptococci and staphylo-
cocci were initially incubated, respectively, either
with 2mg/mL lysozyme (ICN, Oxfordshire, UK)
or with 1mg/L lysostaphin (Sigma) in TE buffer,
for 1 h at 37 8C. Streptococcal isolates were initially
tested for the presence of the methylase determi-
nants ermA/M and ermA [4] in a multiplex PCR,
and the efﬂux determinants mefA/E [5] were
tested in a separate PCR. Isolates that were nega-
tive for these genes were further tested for the
macrolide-resistance genes ermC and msrA/msrB.
The genes and primers used are shown in Table 1.
The composition of the 50-mL PCR-reaction mix
was as follows: 200 nM of each primer (Table 1),
0.2mM of each deoxynucleotide triphosphate
(Amersham Pharmacia, Buckinghamshire, UK),
1U DNA polymerase (DyNAzyme II, Novara
Group Ltd., Ashby de la Zouch, UK), reaction
buffer (10mM Tris–HCl, pH8.8) at 25 8C, 1.5mM
MgCl2, 50mM KCl and 0.1% Triton X-100) and 2 mL
of DNA extract. The ampliﬁcation was performed
in an OmniGene thermal cycler (Hybaid, Ashford,
UK). The denaturation temperature was 93 8C for
30 s, the annealing temperatures were as in Table 1
for 60 s, and extension was at 72 8C for 90 s
for 35 cycles. Positive ampliﬁcation controls
were used for each primer pair and are listed in
Table 2.
Southern blotting
Streptococcal isolates without any of the resistance
genes detected by PCR were tested for the pre-
sence of related genes by Southern blotting with
the mefE and ermA/M genes of the control strains
(Table 2) as probes. These were prepared as above
but with the addition of 1 mL of 100mM solution of
DIG-11-dUTP (Roche Diagnostics Ltd., Lewes,
UK) according to the manufacturer’s protocol.
Fresh DNA was extracted from streptococcal
strains as above and added to the restriction
enzyme HindIII (Fermentas, Lithuania) and incu-
bated at 37 8C for 6 h. The restriction digest was
electrophoresed on a 1% agarose gel overnight and
transferred to a nylon membrane by the technique
described by Southern [14]. The nylon membrane
was incubated with a PCR product according to
the manufacturer’s protocol. Bands were visua-
lized with S-bromo-chloro-3-indolyl phosphate
(BCIP) and nitro blue tetrazolium (NBT) (Roche
Diagnostics Ltd., Lewes, UK).
Table 1 Amplification primers
Gene Oligonucleotide sequence (50 to 30)
Annealing
temperature
Amplified
region Ref
ermA upper: AGAACAATCAATACAGAGTC 48 8C 4656–5282 [6]
lower: TGAACCAGAAAAACCCTAAA
ermA/M upper: TCAACCAAATAATAAAACAA 48 8C 974–1311 [7,8]
lower: AATCCTTCTTCAACAATCAG
mefA/E upper: AGTATCATTAATCACTAGTG 60 8C 371/58–701/388 [9]
lower: TTCTTCTGGTACTAAAAGTGG
ermC upper: ATTTTCTTGTATTCTTTGTT 48 8C 2122–2471 [10]
lower: TTCCTAAAAACCAATCCTAT
msrA/B upper: GTCAAAAACTGCTAACAAG 56 8C 86–428 [11]
lower: AATAATACTGCTAACGATAAT
Table 2 Amplification controls
Strain or plasmid Genotype Source/Reference
S. cohnii
NCTC11041
msrA National Collection
of Type Cultures,
London, UK [12]
S. aureus 2043 ermC methylase Abbotta
S. aureus RN1389 ermA methylase [13]
S. pneumoniae 5728 ermA/M
methylase
Abbott
S. pneumoniae 3894 mefE Abbott
S. pyogenes 1475 mefA Abbott
aCollection of Abbott Laboratories.
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RESULTS
A total of 118 patients were included in the study,
of whom 16 were nonassessable either because no
ﬁrst swab was received (one patient), no follow-up
swabs were received (ﬁve patients), or cultures
were contaminated with yeasts or Gram-negative
bacilli not inhibited by selective media (10
patients). From 22 patients (nine treated with azi-
thromycin and 13 with clarithromycin) only two
swabs were received: these patients were consid-
ered to be partially assessable. From 80 patients (45
receiving azithromycin and 35 receiving clarithro-
mycin) three or four swabs were received: these
patients were deemed fully assessable. There were
delays in the timing of the collection of swabs, as
shown in Figure 1. This affected the fourth swab
particularly, but also the third swab from patients
treated with clarithromycin.
Among the 118 patients, only 14 had no resistant
normal aerobic oral ﬂora in the ﬁrst swab, and a
further 10 patients had only yeasts or Gram-nega-
tive bacilli, but no other resistant organisms in the
ﬁrst swab. There was no signiﬁcant difference (by
the Kolmogorov–Smirnov test [15]) in the quantity
of growth in the four swabs from patients treated
with clarithromycin. In patients treated with azi-
thromycin there was a signiﬁcant increase in the
quantity of growth (P 0.05) between swab 1
compared with swabs 2 and 3 but not between
swab 1 and swab 4.
In total, 749 resistant isolates from assessable
and nonassessable patients were selected for iden-
tiﬁcation. The genera to which these isolates
belonged are shown in Table 3. The nonstrepto-
coccal isolates were not considered further. There
were 474 streptococci, belonging to the species also
listed in Table 3. Thirteen species or species com-
plexes were identiﬁed, among these resistant
streptococcal isolates, with S. salivarius the most
common.
Table 4 shows the numbers of erythromycin-
resistant streptococcal isolates from each group
of samples. They include the isolates with discor-
dant results in E test and agar-dilution MICs since
these were all shown to carry resistance genes;
only two of them showed inducible resistance.
Overall, 41.2% of the patients had streptococci
showing high-level resistance (from 16 to
>128mg/L) and a further 34.3% showing low-
level resistance (MIC 2–8mg/L) to erythromycin
in pretreatment samples (sample 1). Thus only a
quarter of the patients had no resistant strepto-
cocci before macrolide treatment was started.
Table 5 shows the patterns of isolation of resis-
tant streptococci from the 80 assessable patients,
from whom at least three samples were collected.
Only one patient retained a sensitive streptococcal
Figure 1 Times of actual collection of throat samples in relation to the planned time of sampling. Vertical dotted lines:
planned collection days.
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ﬂora throughout (pattern A). The 20 remaining
patients with initially susceptible streptococci
(pattern B) all had resistant streptococci in at
least one further sample, in 14 high level and in
six low level. Of the 27 patients who initially had
streptococci with low-level resistance (pattern C),
14 yielded highly resistant streptococci in subse-
quent samples, and in only three cases were there
no resistant streptococci in ﬁnal samples. Of the 32
patients with highly resistant streptococci in the
ﬁrst sample (pattern D) 22 retained them in the
ﬁnal sample collected and seven had no resistant
streptococci in the ﬁnal sample collected. There
was no striking difference between patients trea-
ted with the two antibiotics, but of 45 assessable
patients treated with azithromycin, eight (18%)
had only sensitive streptococci in the ﬁnal sample,
while of 35 treated with clarithromycin 10 (29%)
had only sensitive streptococci in the ﬁnal sample.
This difference is not statistically signiﬁcant
(w2¼ 1.32, P¼ 0.25). Themean numbers of resistant
streptococcal species identiﬁed per sample were
1.0 (range 0–3) in the ﬁrst, 1.4 (0–4) in the second,
1.2 (0–4) in the third and 1.2 (0–4) in the fourth.
Table 4 also shows genetic mechanisms detected
in the whole collection of resistant streptococci.
Since strains positive for erm genes were not
further tested for mef genes we do not know
how many strains might have had both resistance
mechanisms. The most common genes detected
were mefA/E (228 strains) and ermA/M (219
strains), while seven strains (1.5%) had no detect-
able mechanism. No strains had ermA, ermC, or
msr genes. In general, strains with erythromycin
MICs of <8mg/L had mefA/E while those with
higher MICs had ermA/M. Four isolates, one with
ermA/M and three with mefA/E were negative on
initial PCR but positive when repeated. There
Table 3 Identity of 749 erythromycin-resistant isolates
from throat swabs
Genus/species
No. of
isolates
Percentage
of isolates
Streptococci 474 63
S. salivarius 171
S. parasanguis 110
S. sanguis 45
S. oralis 41
S. sanguis group 22
S. mitis group 21
S. vestibularis 19
S. constellatus 14
S. crista 5
S. intermedius 5
S. anginosus 2
S. gordonii 2
S. mitis 1
Group G streptococcus 1
unidentified 15
Neisseria 64 8.5
Stomatococci 11 1.5
Staphylococci 9 1.2
Corynebacteria 4 0.5
Micrococci 1 0.1
Enterococci 1 0.1
Unidentified Gram-positive bacilli 3 0.4
Unidentified Gram-negative bacilli 85 11.3
Yeasts 97 13
Table 4 Isolation of resistant streptococci from different samples and associated resistance genes in 474 strains
Erythromycin-resistant streptococci from sample no.a
1 (117) 2 (113) 3 (88) 4 (75)
Number of isolates 119 158 104 93
Isolates per sample
mean 1 1.4 1.2 1.2
range 0–3 0–4 0–4 0–4
Number with:
mefA/E 63 75 40 50
ermA/M 45 79 57 38
no detectable mechanism 2 0 3 2
not tested 9 4 4 3
Significance of difference in proportion of mefA/E and ermA/M 0.03 0.7 0.03 0.08
asample no. 1 collected before treatment, no. 2 collected 2days after treatment, no. 3 collected 3weeks after treatment and
no. 4 collected 5–6weeks after treatment.
Numbers in parentheses are the numbers of swabs received.
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was no difference between azithromycin and
clarithromycin in resistance mechanisms asso-
ciated with treatment, but mefA/E was slightly
more common in ﬁrst and ﬁnal samples while
ermA/M was slightly more common in third sam-
ples (Table 4).
DISCUSSION
Our original intentions in this study were
thwarted by two unexpected ﬁndings. The ﬁrst,
largely overcome by the use of selective media
containing either amphotericin or nalidixic acid,
Table 5 Pattern of isolation of resistant streptococci from 80 patients from whom three or four assessable cultures were
obtained
Pattern in sample no. No. of patients treated with
1 2 3 4 azithromycin clarithromycin
A – – – – 1 0
B – R R R 2 2
– R R – 1 3
– R R r 1 0
– r r – 0 3
– r r r 0 2
– R – r 2 0
– R r R 0 1
– – – r 1 0
– r R x 1 0
– R R x 1 0
Total 9 11
C r r r R 2 2
r r – r 4 1
r – r r 0 1
r r r R 1 0
r r r – 1 0
r r R r 2 0
r – R – 0 1
r R R R 3 1
r R R r 0 1
r R R – 0 1
r R r R 1 0
r r R R 0 1
r R – r 1 0
r R – R 0 1
r r r x 1 1
Total 16 11
D R R R R 3 4
R R R – 2 0
R R r R 0 1
R R – r 2 1
R R – R 2 1
R – R R 1 1
R r R R 1 0
R R – – 0 1
R r R – 1 0
R r – R 0 1
R – R – 1 0
R R R x 5 2
R R – x 1 0
R – – x 0 1
Total 19 13
R, high-level erythromycin resistance (MIC from 16 to >128mg/L); r, low-level resistance (MIC 2–8mg/L) in at least one
streptococcal species in the sample; –, no resistant streptococci; x, no sample.
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was the presence of sufﬁciently large numbers of
yeasts or Gram-negative bacilli (which we did not
further identify) that hid the streptococcal ﬂora on
our culture plates. This problem was probably
exacerbated by our use of lawned inocula: under
normal circumstances the yeasts and Gram-nega-
tive bacilli would probably have been diluted out
by streaking. All the same, their presence in gen-
erally healthy adults who had not recently
received antibiotics was surprising. The second
aspect was the presence of macrolide-resistant
viridans streptococci before treatment, in around
three-quarters of the patients. Similar ﬁndings
were reported in a preliminary study by Maskell
and his colleagues in 1990, but not by previous
investigators [16]. Again, since many of our resis-
tant isolates were, like Maskell’s [16], clearly in
minority populations, these may well not have
been picked up by routine plating techniques,
but since we were seeking such populations, our
methods seem to us appropriate. Had we used the
even more sensitive technique of enrichment, we
might have been accused of selecting rather than
detecting resistance. These two problems, but
especially the second, resulted in our study not
being powerful enough (despite our having
recruited the planned numbers of patients) to
detect any possible differences in the ability of
azithromycin and clarithromycin to select resistant
populations of viridans streptococci. There was a
trend for azithromycin to be more often associated
with resistance at the end of the study period, but
there were insufﬁcient numbers of patients with
initially susceptible populations for us to expect or
to achieve statistical signiﬁcance.
The major ﬁndings related to changes in the
resistant ﬂora after treatment, which again were
similar to those of Maskell et al. [16]. The small
number of patients with no resistant streptococci
at the beginning of the study with only one excep-
tion acquired a resistant population and often
retained it for the 4–6 (or more) weeks of the study.
Of 20 such patients, 13 retained resistant strepto-
cocci (seven high-level and six low-level with no
obvious difference between those given different
antibiotics) while seven acquired them and lost
them—and six of these latter patients had received
clarithromycin. Furthermore, of 27 patients with
viridans streptococci showing initial low-level
macrolide resistance, usually as a result of en-
hanced efﬂux (at least, as suggested by their pos-
session of the relevant genes), only three (two
given clarithromycin) had no resistant streptococci
at the end of the study, while eight (ﬁve given
azithromycin) acquired and retained a highly
resistant streptococcal ﬂora, usually associated
with ermA/M genes. Finally, of the 32 patients
who started with highly resistant viridans strep-
tococci, only ﬁve (four of them given azithromy-
cin) lost them by the end of the study while three
patients (two given azithromycin) ﬁnished with
strains with low-level resistance. Thus while hints
of differences between the two drugs emerge,
numbers are too small to make conclusions pos-
sible, and we are unable to report whether adults
behave in the same way as has been reported for
children [1].
It is of interest that not all species of viridans
streptococci appear to be affected equally, even
allowing for the fact that a throat swab is unlikely
to sample the whole upper respiratory tract vir-
idans streptococcal ﬂora. The great majority of the
resistant strains that we isolated were of the Sal-
ivarius or Mitis group [17], although 13 species or
species groups were represented overall, includ-
ing a few isolates of the Anginosus group. Perhaps
not surprisingly, the Mutans group was absent,
though the report of the absence of macrolide
resistance in S. mutans in a recent study in Taiwan
[18], while it was common in other species that we
also isolated, might explain our results as well
as our assumed inefﬁciency of sampling for this
species.
Whatever the changes brought about by a
course of a macrolide antibiotic, if our results
are typical, there exists in the normal respiratory
ﬂora of generally healthy adults, a large pool of
viridans streptococci carrying genes associated
with macrolide resistance, which is increasingly
reported for clinical isolates of these organisms
[19]. It requires no great stretch of the imagination
to conclude that this is a potential source for such
genes in S. pneumoniae and S. pyogenes [4], and that
attention needs to be extended to viridans strep-
tococci when attempts are made to account for the
emergence of macrolide resistance in the respira-
tory pathogens.
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